Thrombus - 2008


Using diagnostic tests
David Fitzmaurice and Janusz Kaczorowsk
pp 1-3
Tests are part of the diagnostic process that includes history, examination and investigation. It has been suggested that within primary care the first two of these processes are most important, yielding around 90% of diagnoses. The specificity of physical signs and symptoms tends to decrease as patients move along the diagnostic pathway from primary to secondary care, as patients in primary care often present with undifferentiated symptoms and signs, at an early stage in the disease process and with a wide differential diagnosis.
Comment: The new anticoagulants cometh
Peter Rose
pp 2-2
While many in the past 40 years have foretold of forthcoming new anticoagulants it does now appear that this new era has finally arrived. The holy grail has always been well defined, namely to develop an anticoagulant that can be taken orally, that does not require laboratory monitoring, does not interact with other medications (including alcohol), with a good safety profile.
Thrombolysis-related haemorrhage: anticoagulant and antiplatelet therapy
Elizabeth A Warburton and Philip L Clatworth
pp 4-5
Stroke is the leading cause of disability in the UK, and a leading cause of death. Thrombolysis using intravenous recombinant tissue plasminogen activator (rt-PA) is the only licensed and proven therapy for acute stroke. If administered early (within three hours of symptom onset), this can reduce death and disability due to ischaemic stroke by about one-third.
Responding to thrombosis guidelines
Andrew D Blann
pp 6-8
In 2007 the government published three documents on the management of venous thromboembolism (VTE): the report of the independent expert working group (IEWG), Report 46 from the National Institute for Health and Clinical Excellence (NICE), and Alert 18 from the National Patient Safety Agency (NPSA).
Transfusion issues surrounding the use of fresh frozen plasma
Barry Hill
pp 10-11
There is no doubt that the now ready availability of blood components such as fresh frozen plasma (FFP) has made a significant contribution to the treatment of haematological bleeding disorders and management of uncontrolled bleeding during trauma situations. However, despite these proven benefits to patients, several safety issues and concerns regarding inappropriate usage, viral or bacterial transmission risks, variant Creutzfeldt–Jakob disease (vCJD) considerations and immune complications of transfusion surround their deployment.

Thrombus was previously supported by Bayer from 2014 to 2016, by Boehringer Ingelheim from 2009 to 2013, by sanofi-aventis from 2007 to 2008 and by Leo Pharma from 1998 to 2006.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsor, publisher, Editor or Editorial Board. Accordingly the sponsor, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Thrombus is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2019 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk

ISSN 1369-8117 (Print)  ISSN 2045-7855 (Online)

Site Map | company profile | contact us | testimonials | current vacancies | © 2011 - 2024 Your Company Name